14 October 2024
Motorika Nemo LLC received perpetual registration certificates for medical devices included in the vagus nerve stimulation system manufactured by Rishena. These devices target drug-resistant epilepsy, a condition that impacts 20-30% of the approximately 50 million individuals living with epilepsy globally.
Rishena Medical is a pioneering Chinese company dedicated to scientific research and development, specializing in the manufacturing and sales of active implantable medical devices. To date, Rishena Medical has registered more than 100 patents and continues to develop new devices. Motorika Nemo LLC is set to launch the VNS201B implantable device for vagus nerve stimulation, along with its accompanying implantable electrode and programmers, in the domestic market.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Vaccines “essential” for addressing AMR, says WHOVaccines “essential” for addressing AMR, says WHO
15 October 2024
Digital biomarkers: reinventing patient monitoring and care
15 October 2024
Chinese medical products for the treatment of epilepsy registered in Russia
14 October 2024
Russia proposes to establish a prize for new drug development technologies
14 October 2024